The thriving artificial intelligence (AI) technology is altering the way how we live and work, and healthcare is the major field on which AI research focuses. On March 24, 2018, Lepu Medical has launched its in-house AI-ECG Platform, an automatic ECG analysis & diagnosis system, in the 16th China Interventional Therapeutics (CIT). The launching testifies that Lepu has stepped close towards the comprehensive AI layout and development on healthcare.

On the press conference of Artificial Intelligence Fuels ECG, the cardiovascular experts, ECG specialists, physicians from lower-ranking hospitals, medical and financial journalists, and partners showed great interest on this auto ECG analysis & diagnosis system.

As commonly known, ECG is the fundamental and indispensable method for cardiovascular diagnosis and assessment. Though the ECG technology of 100 years’ history has been extensively used in the clinician, the ECG signal, of the characteristics of complexity and vulnerability to noise, cannot be accurately identified and diagnosed with the traditional ECG algorithm, but mostly relies on the professional interpretation by physicians. Due to the lacking of experienced ECG physicians in the healthcare institutes, especially the lower-ranking hospitals, the patients there suffering cardiovascular disease may not have the accurate diagnosis and timely treatment.

Lepu Medical aimed at this healthcare weakness. In 2016, Lepu set up the AI technology team, and collected thousands of big data samples from patients’ ECG for AI model training and establishing. The AI-ECG Platform is the fruit of team’s hard work and endeavor. Based on the deep-learning, the system is sensitive to arrhythmias, especially tachycardia, escape beat, conduction block, atrial fibrillation and atrial flutter.

The AI-ECG Platform is expected to get robust online and offline promotions in domestic market. In addition, the Platform is the first chinese innovative medical device in the AI ECG field with FDA clearance and CE certification.